Better results from better imaging

Any clinical trials involving white matter will benefit from our capabilities.

What we




At Imeka, we use non-invasive, advanced white matter MRI to image white matter and:

Measure three key markers of neuropathology: neuroinflammation, axonal degeneration, and demyelination;

Measure therapeutic effects, such as remyelination and
tissue repair;

Provide virtual dissection of 50+ different fiber bundles—robust to crossing fibers.

The ultimate goal of white matter imaging is to find non-invasive and indirect markers that are sensitive to pathology and are able to quantify damage and/or therapeutic changes. Imeka’s ANIE (Advanced Neuro Imaging Endpoints) biomarker platform achieves that goal.

How we measure neuroinflammation,
axonal degeneration, and demyelination

Our proprietary analytic algorithm and well-trained artificial intelligence work together to identify and quantify white matter pathology and integrity.

Imeka’s biomarker and diagnostic potential

Imeka can give you precise micro- and macrostructure information about the white matter before clinical signs.

What if you could locate and measure the effect of a therapy before even seeing a clinical difference? What if you could quantify a clinical effect in a specific area of the brain, instead of having your data diluted by whole-brain measurements?

Imagine a future where a person can lie down in an MRI machine and find out if they’re slowly developing Parkinson’s disease. Or a patient can discover that their Alzheimer’s disease subtype is almost certain to respond to a specific therapy. We can identify such things for other diseases, like diabetes or gene-identified cancer. Let’s make this true in neurology, too.


We can identify and quantify neuroinflammation, axonal degeneration, and myelin indexes throughout the white matter and down to the fiber level.

These capabilities mean that Imeka’s ANIE (Advanced Neuro Imaging Endpoints) biomarker platform has applications across the spectrum of central nervous system diseases, and we are always looking for exciting new things to discover.

Our biomarkers are most advanced in the following disease areas:

Alzheimer’s disease (AD)

There is a desperate need for better diagnostic tools and treatment options for AD. We believe our capabilities and biomarkers can make a real difference in the diagnosis and treatment of AD.

Here’s what we can see in AD:

Connections to and from the following regions:

  • Medial temporal bundles
  • Corpus callosum
  • Posterior cingulum


  • Neuroinflammation
  • Axonal degeneration
  • Myelin index

Multiple Sclerosis (MS)

White matter lesions traditionally define MS—but what is happening in the normal-appearing white matter? Our imaging and tracing abilities shed light on the mysteries of MS to help improve how we treat it.

Here’s what we can see in MS:

Pathologies that are:

  • Lesion-load dependent and patient specific
  • In the normal-appearing white matter


  • Myelin index
  • Neuroinflammation
  • Axonal degeneration

Parkinson’s disease (PD)

The understanding and treatment of PD are both severely lacking. Better and earlier brain imaging can help us understand and learn to treat PD.

Here’s what we can see in PD:

Connections to and from the following regions:

  • Substantia nigra
  • Motor cortex
  • Thalamus
  • Brainstem


  • Neuroinflammation
  • Axonal degeneration
  • Myelin index

Have a product in the pipeline?
We know how to work with you!

Imeka has first-hand understanding of the pharma ecosystem and its intricacies. Thanks to our ongoing and past projects with biopharma companies, we know what questions to ask and how to get things done in your framework.


How Imeka’s ANIE biomarker-generating platform works

Fundamentally, the ANIE biomarker platform is a proprietary software algorithm that incorporates artificial intelligence (AI) to analyze and extract information from advanced white matter imaging data.

  • The software was developed through a collaboration between two experts in their field: Maxime Descoteaux, who is a white matter imaging specialist, and Pierre-Marc Jodoin, who is a deep learning specialist.
  • The AI component of Imeka’s ANIE biomarker platform was trained on a combination of atlases, open-source MRI databases, and proprietary databases.

The software and AI training approach are unique to and owned by Imeka—with several patents pending.

Thanks to its unique processing abilities, Imeka’s ANIE biomarker platform can efficiently and accurately:

  • Identify key differences between two groups (for example, a control group vs. a treatment group, or a patient group vs. healthy controls);
  • Identify longitudinal changes on a per-patient basis; and
  • Function as a biomarker-generating platform.

Our software is best in class at identifying white matter pathology and detecting changes.
Let’s see what we can do together.

Let’s collaborate!

Like you, our main goal is to play an influential role—and minimize risk—in the search for and development of cures for brain diseases. Let’s see what we can do together.

Contact us